Nab-Paclitaxel Shows Greater Benefit Than Paclitaxel in Breast Cancer Subsets

According to results from the GeparSepto Trial, nab-paclitaxel proves to be more beneficial than paclitaxel in certain subsets of breast cancer. In particular, in patients with triple-negative breast cancer nab-paclitaxel showed almost a doubling of the PCR rate compared with paclitaxel.

 Targeted Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.